SCHEDULE: Biofrontera AG Converts Preferred Stock, Boosts Stake

Biofrontera AG has converted Series D Preferred Stock into common shares of Biofrontera Inc., increasing its beneficial ownership to 19.54% and securing board representation rights.

Summary

• Biofrontera AG (BFAG) converted Series D Convertible Preferred Stock into common shares of Biofrontera Inc. following stockholder approval on September 16, 2025.
• This conversion stems from an agreement where Biofrontera Inc. acquired U.S. rights to Ameluz and RhodoLED from BFAG, in exchange for 3,019 shares of Series D Preferred Stock.
• The Series D Preferred Stock is convertible into common stock at a rate of $1,000 divided by $0.6249 per share, totaling a maximum of 4,831,172 common shares.
• BFAG's current beneficial ownership, including 400,000 existing shares and 2,093,346 convertible shares (subject to a 19.99% cap), stands at 2,493,346 common shares, representing 19.54% of the class.
• Deutsche Balaton Aktiengesellschaft (DB) and related entities beneficially own 2,552,230 shares, or 19.99% of the class, due to their direct holdings and control relationships with BFAG.
• The agreement also established a royalty structure for Ameluz U.S. revenue: 12% for revenue below $65.0 million and 15% for revenue exceeding $65.0 million, replacing a previous transfer pricing model.

Sentiment

Score: 6

Explanation: The filing confirms the expected conversion of preferred stock and the associated beneficial ownership, which is a neutral event in itself. However, the ongoing litigation in Germany and the historical dilution experienced by BFAG introduce elements of uncertainty and past negative events, while the secured board representation and new royalty structure are positive for BFAG. The overall sentiment is moderately positive due to the clarity provided on the ownership structure and the strategic benefits of the royalty agreement, despite the lingering legal issue.

Positives

• Stockholder approval for Series D Preferred Stock conversion allows BFAG to realize its equity stake from the U.S. rights acquisition.
• BFAG secures the right to appoint one or two members to Biofrontera Inc.'s board of directors for three years, enhancing its influence.
• The new royalty structure for Ameluz U.S. revenue provides a clear, performance-based income stream for BFAG.

Negatives

• BFAG's ownership was substantially diluted by Biofrontera Inc.'s previous equity issuances and a 1-for-20 reverse stock split.
• A pending legal proceeding in Germany challenges the validity of BFAG's board resolutions regarding Biofrontera Inc.'s IPO, creating uncertainty.
• The 19.99% conversion cap on Series D Preferred Stock limits BFAG's immediate ability to fully convert its preferred shares into common stock.

Risks

• Litigation Risk: An ongoing appeal to the Federal Supreme Court in Germany regarding the validity of BFAG's board resolutions for Biofrontera Inc.'s IPO could have unforeseen consequences.
• Conversion Cap Risk: The 19.99% beneficial ownership cap restricts BFAG's immediate ability to convert all its Series D Preferred Stock, potentially limiting its upside or control.
• Market Conditions Risk: DB's intention to acquire or dispose of additional voting securities is subject to market conditions, introducing variability.
• Dilution Risk: Biofrontera Inc.'s history of substantial dilution through equity issuances and reverse stock splits could continue to impact shareholder value.

Future Outlook

Deutsche Balaton Aktiengesellschaft (DB) currently intends to acquire additional voting securities of Biofrontera Inc., or instruments convertible into voting securities, as deemed desirable for investment purposes, subject to market conditions. Biofrontera AG (BFAG) may elect to increase its beneficial ownership conversion cap up to 49.99% after providing 61 days' written notice to Biofrontera Inc.

Management Comments

• There is no agreement among the Reporting Persons, written or oral, with respect to the acquisition, ownership, voting or disposition of any securities of the Issuer, and the Reporting Persons disclaim the existence of any group among them within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934.
• DB sought to offset in part the economic dilution resulting to BFAG (and, indirectly, to BFAG's shareholders) as a result of the Issuer's repeated issuances of common stock and warrants.

Industry Context

The biopharmaceutical industry, particularly dermatology, often involves complex licensing agreements and royalty structures for product commercialization. The shift from a transfer pricing model to a royalty-based system for Ameluz and RhodoLED U.S. rights reflects a common strategy to align incentives and simplify financial arrangements between parent and subsidiary or licensing partners. The ongoing litigation in Germany highlights potential corporate governance challenges that can arise in cross-border corporate structures, especially concerning IPO approvals and shareholder rights.

Comparison to Industry Standards

• The royalty rates of 12% and 15% for Ameluz U.S. revenue are within the typical range for pharmaceutical product licensing agreements, which can vary widely based on development stage, market potential, and negotiation leverage. For instance, early-stage drug candidates might command lower single-digit royalties, while established, high-revenue products can see royalties in the high teens or even low twenties.
• The 19.99% beneficial ownership cap is a common defensive measure in U.S. public companies to prevent triggering certain shareholder rights plans ("poison pills") or other change-of-control provisions without board approval. Companies like Sarepta Therapeutics or Alnylam Pharmaceuticals have seen similar caps or standstill agreements in their investor relations.
• The right for a significant shareholder (BFAG) to appoint board members is a standard corporate governance practice, especially when a company has spun off from a larger entity or has a major strategic investor. This is comparable to arrangements seen in companies like Viatris (post-Pfizer Upjohn spin-off) or certain biotech firms with venture capital representation.

Management Changes

Corporate Governance

Legal Proceedings

• Deutsche Balaton Aktiengesellschaft (DB) filed an action against Biofrontera AG (BFAG) with the local court of Cologne, Germany, arguing that BFAG's board resolutions regarding Biofrontera Inc.'s IPO required general meeting approval.
• The local court ruled BFAG's board resolutions for the IPO were void.
• An appeal to the Higher Regional Court of Cologne, Germany, rejected the litigation but permitted a further appeal to the Federal Supreme Court.
• DB has lodged an appeal to the Federal Supreme Court, and the litigation is currently pending there.

Related Party Transactions

• Biofrontera Inc. acquired U.S. rights to Ameluz and RhodoLED from Biofrontera AG (BFAG) and its subsidiaries.
• In exchange, BFAG received 3,019 shares of Biofrontera Inc.'s Series D Convertible Preferred Stock and a new royalty agreement (12% or 15% of Ameluz U.S. revenue).
• Deutsche Balaton Aktiengesellschaft (DB) directly holds 58,884 shares of Biofrontera Inc. common stock and, through its ownership and control relationships with BFAG, is deemed to beneficially own BFAG's shares.
• VV Beteiligungen Aktiengesellschaft (VVB) owns a majority interest in DB.
• Delphi Unternehmensberatung Aktiengesellschaft (DU) owns a majority interest in VVB and directly holds a 19.6% voting interest in BFAG.
• Wilhelm Konrad Thomas Zours owns a majority interest in DU and holds management positions in VVB and DU.
• Alexander Link is a management board member of DB and chairman of BFAG's supervisory board.
• Hansjoerg Plaggemars is a management board member of VVB and DU, and a supervisory board member of BFAG.
• Maria del Pilar de la Huerta Martinez is the sole management board member of BFAG.
• A Non-Domination Agreement between VVB and DB limits VVB's voting control over DB to 45%.

Stakeholder Impact

• Shareholders (Biofrontera Inc.): The conversion of preferred stock increases the potential for dilution of common shareholders, especially if BFAG increases its conversion cap. The new royalty agreement could impact Biofrontera Inc.'s profitability depending on Ameluz revenue. The ongoing litigation against BFAG could introduce reputational or operational risks if it impacts the relationship between the entities.
• Shareholders (Biofrontera AG): The conversion of Series D Preferred Stock into common shares provides BFAG with a more liquid equity stake in Biofrontera Inc. and the new royalty structure offers a direct revenue stream. The board representation right enhances BFAG's ability to protect its investment.
• Management (Biofrontera Inc.): The addition of BFAG-appointed directors will alter the board's composition and potentially influence strategic decisions.
• Customers: The agreement for U.S. rights to Ameluz and RhodoLED aims to streamline commercialization, potentially benefiting customers through more focused marketing and distribution.

Next Steps

• BFAG may elect to convert its Series D Preferred Stock into common stock at any time, subject to the 19.99% beneficial ownership cap.
• BFAG may elect to increase the Maximum Percentage for conversion up to 49.99%, which would become effective 61 days after written notice to Biofrontera Inc.
• Deutsche Balaton Aktiengesellschaft (DB) intends to acquire additional voting securities of Biofrontera Inc. or convertible instruments, subject to market conditions.
• The appeal lodged by DB to the Federal Supreme Court in Germany regarding BFAG's IPO board resolutions is pending.

Key Dates

Recommendation

The filing primarily details the mechanics of a previously announced transaction (conversion of Series D Preferred Stock) and clarifies beneficial ownership stakes. While the increased ownership and board representation for Biofrontera AG (BFAG) are notable, they largely reflect the expected outcome of the U.S. rights acquisition. The ongoing litigation in Germany introduces a degree of uncertainty, but its direct impact on Biofrontera Inc.'s current operations or valuation is not immediately clear from this filing. Deutsche Balaton's stated intent to potentially acquire more shares is a positive signal, but it's conditional on market conditions. Given the lack of new, significant operational or financial news, and the mixed implications of the ownership structure and legal proceedings, a 'hold' recommendation is appropriate as investors await further clarity on the litigation and Biofrontera Inc.'s financial performance under the new royalty structure.

Keywords

Biofrontera Inc., Biofrontera AG, Schedule 13D, Beneficial Ownership, Series D Preferred Stock, Common Stock Conversion, Ameluz, RhodoLED, SEC Filing, Biopharmaceutical, Dermatology, Corporate Governance, Shareholder Activism, Royalty Agreement